Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
Status:
Completed
Trial end date:
2018-03-21
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics,
pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that
harbor an IDH1 and/or IDH2 mutation